RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing alternative treatments for conditions ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. The ...

Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to ...

University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...

Management will participate in a fireside chat on Tuesday, March 3, 2026, at 11:50 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, ...

Alnylam took the wraps off its fourth-quarter and full-year 2025 results before market open. These revealed that the ...

Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% response rate. Analysts maintain Buy ratings as shares trade near 52-week lows.

Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping biotech today.

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...